

Daclatasvir**Section**

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 30 mg (as dihydrochloride); 60 mg (as dihydrochloride)

Indications

Chronic hepatitis C

Daclatasvir + sofosbuvir**Section**

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg

Indications

Chronic hepatitis C

Glecaprevir + pibrentasvir**Section**

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid: 50 mg + 20 mg granules
- Oral > Solid > tablet: 100 mg + 40 mg

Indications

Chronic hepatitis C

Ravidasvir**Section**

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg

Indications

Chronic hepatitis C

Sofosbuvir**Section**

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg; 400 mg
- Oral > Solid > granules: 200 mg in sachet

Indications

Chronic hepatitis C

Sofosbuvir + velpatasvir**Section**

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg
- Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet

Indications

Chronic hepatitis C

